Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 601–700 of 4,628
Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib
Bellamri, N., Morzadec, C., Joannes, A., Lecureur, V., Wollin, L., Jouneau, S., & Vernhet, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.061 · Cited by 74
Heukels, P., van Hulst, J. A. C., van Nimwegen, M., Boorsma, C. E., Melgert, B. N., von der Thüsen, J. H., van den Blink, B., Hoek, R. A. S., Miedema, J., Neys, S. F. H., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1195-7 · Cited by 80
“Current disease modifying therapy consists of two drugs that slow down progression of fibrosis [5, 6].”
Backgroundfor the EMPIRE registry, Tran, T., Šterclová, M., Moğulkoç, N., Lewandowska, K. B., Müller, V., Hájková, M., Kramer, M. R., Jovanović, D., Tekavec-Trkanjec, J., et al. (2020) · Respiratory Research · doi:10.1186/s12931-019-1271-z · Cited by 79
Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis
Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B., & Staab-Weijnitz, C. A. (2022) · Cells · doi:10.3390/cells11061050 · Cited by 68
Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
Lee, J. H., Park, H. J., Kim, S., Kim, Y., & Kim, H. C. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02340-8 · Cited by 72
Update on therapeutic management of idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s69716 · Cited by 78
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
Huang, Y., Ma, S., Vij, R., Oldham, J. M., Herazo‐Maya, J. D., Broderick, S. M., Strek, M. E., White, S. R., Hogarth, D. K., Sandbo, N. K., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0142-8 · Cited by 77
Westergren‐Thorsson, G., Hedström, U., Nybom, A., Tykesson, E., Åhrman, E., Hornfelt, M., Maccarana, M., Kuppevelt, T. H. V., Dellgren, G., Wildt, M., et al. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.12.005 · Cited by 71
Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., & Saarto, T. H. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0738-x · Cited by 75
Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases
Ackermann, M., Stark, H., Neubert, L., Schubert, S., Borchert, P., Linz, F., Wagner, W. L., Stiller, W., Wielpütz, M. O., Hoefer, A., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00933-2019 · Cited by 80
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial
West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., et al. (2023) · Thorax · doi:10.1136/thorax-2022-219391 · Cited by 67
Self-citationBonella, F., Kreuter, M., Hagmeyer, L., Neurohr, C., Keller, C., Kohlhaeufl, M. J., Müller–Quernheim, J., Milger, K., & Prasse, A. (2016) · Respiration · doi:10.1159/000448288 · Cited by 73
Danazol Treatment for Telomere Diseases
Townsley, D. M., Bogdan, D., & Young, N. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1607752 · Cited by 74
Intestinal fibrosis: ready to be reversed
Latella, G., & Rieder, F. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000363 · Cited by 76
Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
Griffiths, K. R., Habiel, D. M., Jaffar, J., Binder, U., Darby, W. G., Hosking, C. G., Skerra, A., Westall, G. P., Hogaboam, C. M., & Foley, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-20811-5 · Cited by 78
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management
Hallowell, R. W., & Paik, J. J. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/brvl1v · Cited by 77
Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E., Sand, J. M. B., & Shaker, S. B. (2021) · Respiratory Research · doi:10.1186/s12931-021-01801-0 · Cited by 65
Campochiaro, C., & Allanore, Y. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02536-5 · Cited by 76
Gu, Y., Lawrence, T., Mohamed, R., Liang, Y., & Yahaya, B. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923235 · Cited by 77
“Although two drugs, namely Nintedanib and Pirfenidone, are recognised as effective therapies for this disease (9, 10), they only alleviate disease progression and do not address damage that has already occurred.”
BackgroundKhor, Y. H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201611-934oc · Cited by 69
Wu, A. C., Kiley, J. P., Noel, P. J., Amur, S., Burchard, E. G., Clancy, J. P., Galanter, J., Inada, M., Jones, T. K., Kropski, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1895st · Cited by 67
Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis
Barnes, J. W., Duncan, D., Helton, S., Hutcheson, S. B., Kurundkar, D., Logsdon, N. J., Locy, M. L., Garth, J. M., Denson, R. S., Farver, C. F., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00246.2018 · Cited by 72
Yu, X., Li, X., Wang, L., Liu, R., Xie, Y., Li, S., & Li, J. (2019) · BioMed Research International · doi:10.1155/2019/8498603 · Cited by 73
Buono, M. G. D., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R. A., Crea, F., et al. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.011 · Cited by 73
Karampitsakos, Τ., Torrisi, S. E., Antoniou, K. M., Manali, E. D., Korbila, I. P., Παπαϊωάννου, Ο., Sampsonas, F., Katsaras, M., Vasarmidi, E., Papakosta, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01725-9 · Cited by 76
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
Jo, H. E., Randhawa, S., Corte, T. J., & Moodley, Y. P. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0366-1 · Cited by 79
Epigenetics in lung fibrosis: from pathobiology to treatment perspective
Helling, B. A., & Yang, I. V. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000191 · Cited by 70
German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2018) · Pneumologie · doi:10.1055/s-0043-123035 · Cited by 71
Self-citationMaden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 65
Weatherley, N. D., Stewart, N. J., Chan, H.-F., Austin, M., Smith, L. J., Collier, G., Rao, M., Marshall, H., Norquay, G., Renshaw, S. A., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-211851 · Cited by 66
Stem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0308-z · Cited by 65
Yamanaka, T., Harimoto, N., Yokobori, T., Muranushi, R., Hoshino, K., Hagiwara, K., Gantumur, D., Handa, T., Ishii, N., Tsukagoshi, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0744-7 · Cited by 75
Nandy, S., Raphaely, R. A., Muniappan, A., Shih, A. R., Roop, B. W., Sharma, A., Keyes, C. M., Colby, T. V., Auchincloss, H. G., Gaissert, H. A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202104-0847oc · Cited by 71
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
Samarelli, A. V., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., Manicardi, L., Moretti, A., Tabbì, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168952 · Cited by 72
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
Maher, T. M., Avram, C., Bortey, E., Hart, S. P., Hirani, N., Molyneux, P. L., Porter, J. C., Smith, J. A., & Sciascia, T. R. (2023) · NEJM Evidence · doi:10.1056/evidoa2300083 · Cited by 76
Ohkubo, H., Kanemitsu, Y., Uemura, T., Takakuwa, O., Takemura, M., Maeno, K., Ito, Y., Oguri, T., Kazawa, N., Mikami, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152505 · Cited by 77
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 69
Self-citationMacitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
Bellaye, P., Yanagihara, T., Granton, E., Sato, S., Shimbori, C., Upagupta, C., Imani, J., Hambly, N., Ask, K., Gauldie, J., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01857-2017 · Cited by 72
Self-citationMesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination
Chuang, H.-M., Shih, T. E., Lu, K.-Y., Tsai, S.-F., Harn, H., & Ho, L. (2018) · Cell Transplantation · doi:10.1177/0963689718787501 · Cited by 66
Behr, J., Kolb, M. R. J., Song, J. W., Luppi, F., Schinzel, B., Stowasser, S., Quaresma, M., & Martínez, F. J. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0488oc · Cited by 64
Self-citationMicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis
Mizuno, K., Mataki, H., Seki, N., Kumamoto, T., Kamikawaji, K., & Inoue, H. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.98 · Cited by 64
O’Dwyer, D. N., Norman, K. C., Xia, M., Huang, Y., Gurczynski, S. J., Ashley, S. L., White, E. S., Flaherty, K. R., Martínez, F. J., Murray, S., et al. (2017) · Scientific Reports · doi:10.1038/srep46560 · Cited by 71
Self-citationNolan, C. M., Birring, S. S., Maddocks, M. M., Maher, T. M., Patel, S., Barker, R. E., Jones, S. E., Walsh, J. A., Wynne, S. C., George, P. M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00281-2019 · Cited by 65
Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Casa, G. D., Salvarani, C., & Manfredi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020407 · Cited by 74
Takehara, K., Koga, Y., Hachisu, Y., Utsugi, M., Sawada, Y., Saito, Y., Yoshimi, S., Yatomi, M., Shin, Y., Wakamatsu, I., et al. (2022) · Cells · doi:10.3390/cells11010143 · Cited by 64
Sisson, T. H., Christensen, P. J., Muraki, Y., Dils, A. J., Chibucos, L., Subbotina, N., Tohyama, K., Horowitz, J. C., Matsuo, T., Bailie, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13753 · Cited by 62
“Therefore, the approval of the first two drugs for patients with IPF, the prototypic scarring disorder of the lung, created excitement in the pulmonary community (King et al. 2014; Richeldi et al. 2014).”
BackgroundKim, G. H. J., Weigt, S. S., Belperio, J. A., Brown, M. S., Shi, Y., Lai, J. H., & Goldin, J. G. (2019) · European Radiology · doi:10.1007/s00330-019-06402-6 · Cited by 71
Kalluri, M., Luppi, F., & Ferrara, G. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.032 · Cited by 64
“Jo ur na l P re -p ro of measures such as lung function, and PROMs have only been used as secondary endpoints.(30,31) The past decade has seen an increase in PROMs use in idiopathic pulmonary fibrosis, generally including dyspnea and cough questionnaires, quality of life measures and depression/anxiety questionnaires.”
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
Sun, M., Sun, Y., Feng, Z., Kang, X., Yang, W., Wang, Y., & Luo, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105635 · Cited by 72
Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Ghazipura, M., Mammen, M. J., Herman, D. D., Hon, S. M., Bissell, B. D., Macrea, M. M., Kheir, F. M., Khor, Y. H., Knight, S. L., Raghu, G., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-343oc · Cited by 69
Self-citationCaminati, A., Madotto, F., Cesana, G., Conti, S., & Harari, S. A. (2015) · European Respiratory Review · doi:10.1183/16000617.0040-2015 · Cited by 72
Surolia, R., Li, F. J., Wang, Z., Li, H., Liu, G., Zhou, Y., Luckhardt, T., Bae, S., Liu, R.-M., Rangarajan, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91377 · Cited by 69
Li, L., Kao, K., Liu, Y.-Y., Lin, C., Chen, N., Lee, C.-S., Wang, C., & Yang, C. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13206 · Cited by 71
The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Weng, D., Chen, X., Qiu, H., Zhang, Y., Li, Q., Zhao, M., Wu, Q., Chen, T., Hu, Y., Wang, L.-S., et al. (2019) · Mediators of Inflammation · doi:10.1155/2019/5160694 · Cited by 73
“While we do not have follow-up lung function data from all AE-IPF patients except the information about their death, our follow-up data of stable IPF patients show a one-year decline in FVC (270 ± 206ml) similar to recent studies [21, 22].”
BackgroundResultSelf-citationInterstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis
Hunninghake, G. M. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212446 · Cited by 67
Management of Idiopathic Pulmonary Fibrosis
Pleasants, R., & Tighe, R. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862497 · Cited by 63
“and in INPULSIS-2, but not in INPULSIS-1.(38) Based on pooled data from the INPULSIS trials, the incidence rate of investigator-reported acute exacerbations was 5.”
BackgroundThe genetics of interstitial lung diseases
Borie, R., Guen, P. L., Ghanem, M., Taillé, C., Dupin, C., Dieudé, P., Kannengiesser, C., & Crestani, B. (2019) · European Respiratory Review · doi:10.1183/16000617.0053-2019 · Cited by 79
Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis
Umeda, Y., Demura, Y., Morikawa, M., Anzai, M., Kadowaki, M., Ameshima, S., Tsuchida, T., Tsujikawa, T., Kiyono, Y., Okazawa, H., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.163360 · Cited by 62
Liu, H., Du, K., Li, D., Du, Y., Xi, J., Xu, Y. D., Shen, Y., Jiang, T., & Webster, T. J. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s181002 · Cited by 65
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
Luo, Y., Xu, W., Chen, H., Warburton, D., Dong, R., Qian, B., Selman, M., Gauldie, J., Kolb, M. R. J., & Shi, W. (2015) · The Journal of Pathology · doi:10.1002/path.4530 · Cited by 64
Self-citationKreuter, M., Herth, F. J. F., Wacker, M. E., Leidl, R., Hellmann, A., Pfeifer, M. A., Behr, J., Witt, S., Kauschka, D., Mall, M. A., et al. (2015) · BioMed Research International · doi:10.1155/2015/123876 · Cited by 77
Lung transplantation in idiopathic pulmonary fibrosis
Kumar, A., Kapnadak, S. G., Girgis, R. E., & Raghu, G. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1462704 · Cited by 76
Self-citationFGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro
Zhang, S., Yu, D., Wang, M., Huang, T., Wu, H., Zhang, Y., Zhang, T., Wang, W., Yin, J., Ren, G., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.100 · Cited by 64
Dutta, P., Funston, W., Mossop, H., Ryan, V., Jones, R., Forbes, R., Sen, S., Pearson, J. P., Griffin, S. M., Smith, J. A., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212102 · Cited by 69
Mammarappallil, J. G., Rankine, L. J., Wild, J. M., & Driehuys, B. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000392 · Cited by 67
Moor, C. C., Wijsenbeek, M. S., Balestro, E., Biondini, D., Bondue, B., Cottin, V., Flewett, R., Galvin, L., Jones, S., Molina‐Molina, M., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00124-2019 · Cited by 64
Self-citationAntoniou, K. M., Markopoulou, K., Tzouvelekis, A., Trachalaki, A., Vasarmidi, E., Organtzis, J., Tzilas, V., Bouros, E., Kounti, G., Rampiadou, C., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00172-2019 · Cited by 68
Lambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19294-1 · Cited by 61
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Ali, M. F., Egan, A. M., Shaughnessy, G. F., Anderson, D. K., Kottom, T. J., Dasari, H., Keulen, V. P. V., Aubry, M.-C., Yi, E. S., LIMPER, A. H., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0387oc · Cited by 69
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F. C., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01857-y · Cited by 71
Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy
Yang, M., Lin, Y.-J., Han, M., Bi, Y., He, X.-Y., Xing, L., Jeong, J., Zhou, T., & Jiang, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.054 · Cited by 63
Lou, Y., Zou, X., Pan, Z., Huang, Z., Zheng, S., Xiaowei, Z., Yang, X., Bao, M., Zhang, Y., Gu, J., et al. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae058 · Cited by 69
Peng, X., Moore, M. W., Mathur, A., Zhou, Y., Sun, H., Gan, Y., Herazo‐Maya, J. D., Kaminski, N., Hu, X., Pan, H., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600373r · Cited by 65
“Whereas in some situations treatment with antifibrotic agents can attenuate the decline in ventilatory function caused by IPF, benefits are limited, heterogeneous, and accompanied by significant toxicities (9, 10).”
BackgroundThe role of high-resolution computed tomography in the follow-up of diffuse lung disease
Elicker, B. M., Kallianos, K. G., & Henry, T. S. (2017) · European Respiratory Review · doi:10.1183/16000617.0008-2017 · Cited by 63
Hariri, L. P., Adams, D. C., Wain, J. C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1446le · Cited by 61
Nakano, A., Ohkubo, H., Taniguchi, H., Kondoh, Y., Matsuda, T., Yagi, M., Furukawa, T., Kanemitsu, Y., & Niimi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-59100-5 · Cited by 70
Self-citationEnomoto, Y., Matsushima, S., Shibata, K., Aoshima, Y., Yagi, H., Meguro, S., Kawasaki, H., Kosugi, I., Fujisawa, T., Enomoto, N., et al. (2018) · Clinical Science · doi:10.1042/cs20180435 · Cited by 60
Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?
Stump, B., Cui, Y., Kidambi, P., Lamattina, A. M., & El‐Chemaly, S. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0290tr · Cited by 61
Kishi, M., Aono, Y., Sato, S., Koyama, K., Azuma, M., Abe, S., Kawano, H., Kishi, J., Toyoda, Y., Okazaki, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209786 · Cited by 70
Amati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., & Aliberti, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097849 · Cited by 64
“Notably, in both SENESCIS and INBUILD trials, curves for FVC change from baseline separated by week 12 and continued to diverge since the end of the study, similarly to nintedanib trials in IPF [4,9,10].”
BackgroundResultEffects of nintedanib on symptoms in patients with progressive pulmonary fibrosis
Wijsenbeek, M. S., Swigris, J. J., Inoue, Y., Kreuter, M., Maher, T. M., Suda, T., Baldwin, M., Mueller, H., Rohr, K. B., & Flaherty, K. R. (2023) · European Respiratory Journal · doi:10.1183/13993003.00752-2023 · Cited by 67
Self-citationHypoxia-sensitive pathways in inflammation-driven fibrosis
Manresa, M. C., Godson, C., & Taylor, C. T. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00349.2014 · Cited by 59
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
Conforti, F., Davies, E. R., Calderwood, C., Thatcher, T. H., Jones, M. G., Smart, D. E., Mahajan, S., Alzetani, A., Havelock, T., Maher, T. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17114 · Cited by 62
Self-citationTherapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 62
Gabasa, M., Ikemori, R., Hilberg, F., Reguart, N., & Alcaraz, J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.270 · Cited by 65
“In addition to lung ADC, nintedanib has been recently approved to treat patients with idiopathic pulmonary fibrosis (IPF), based on its ability to slow the progression of this rare disease in clinical trials (Richeldi et al, 2014; Wollin et al, 2015).”
BackgroundTreatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis
Fidler, L. M., Sitzer, N., Shapera, S., & Shah, P. S. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.03.008 · Cited by 62
The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice
Boots, A. W., Veith, C., Albrecht, C., Bartholomé, R., Drittij-Reijnders, M.-J., Claessen, S. M. H., Bast, A., Rosenbruch, M., Jonkers, L., van Schooten, F., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1142-x · Cited by 64
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59
Self-citationMaher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina‐Molina, M., Axmann, J., Kirchgaessler, K.-U., & Cottin, V. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000289 · Cited by 62
Self-citationRenaud, L., da Silveira, W. A., Takamura, N., Hardiman, G., & Feghali‐Bostwick, C. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00383 · Cited by 64
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis
Tsoyi, K., Liang, X., Rossi, G. D., Ryter, S. W., Xiong, K., Chu, S. G., Liu, X., Ith, B., Celada, L. J., Romero, F., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3100oc · Cited by 62
Ageing mechanisms that contribute to tissue remodeling in lung disease
Schuliga, M. J., Read, J. M., & Knight, D. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101405 · Cited by 65
Yamakawa, H., Ogura, T., Kameda, H., Kishaba, T., Iwasawa, T., Takemura, T., & Kuwano, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173806 · Cited by 73
Acute and subacute idiopathic interstitial pneumonias
Taniguchi, H., & Kondoh, Y. (2016) · Respirology · doi:10.1111/resp.12786 · Cited by 61
Self-citationSix-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
Ashley, S. L., Xia, M., Murray, S., O’Dwyer, D. N., Grant, E. P., White, E. S., Flaherty, K. R., Martínez, F. J., & Moore, B. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159878 · Cited by 69
Self-citation
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.